Valuation: Pharmsynthez

Market Cap 1.98B 24.03M 21.83M 20.17M 18.22M 34.38M 2.26B 35.59M 243M 96.11M 1.21B 90.17M 88.26M 3.84B P/E 2024
7.8x
P/E 2025 -7.81x
Enterprise Value 2.34B 28.39M 25.79M 23.83M 21.52M 40.62M 2.67B 42.04M 287M 114M 1.43B 107M 104M 4.53B EV / Sales 2024
9.48x
EV / Sales 2025 15x
Free-Float
95.22%
Yield 2024 *
-
Yield 2025 -
11-02 Public Joint-Stock Company "Pharmsynthez" Reports Earnings Results for the Nine Months Ended September 30, 2026 CI
08-02 Public Joint-Stock Company "Pharmsynthez" Reports Earnings Results for the Half Year Ended June 30, 2026 CI
06-02 Public Joint-Stock Company "Pharmsynthez" Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
05-07 Public Joint-Stock Company "Pharmsynthez" Reports Earnings Results for the Full Year Ended December 31, 2025 CI
11-27 Public Joint-Stock Company "Pharmsynthez" Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
29/08/25 Public Joint-Stock Company "Pharmsynthez" Reports Earnings Results for the Half Year Ended June 30, 2025 CI
27/09/23 Public Joint-Stock Company "Pharmsynthez" Reports Earnings Results for the Half Year Ended June 30, 2023 CI
18/05/23 Public Joint-Stock Company "Pharmsynthez" Auditor Raises 'Going Concern' Doubt CI
18/05/23 Public Joint-Stock Company "Pharmsynthez" Reports Earnings Results for the Full Year Ended December 31, 2022 CI
07/11/22 Public Joint-Stock Company "Pharmsynthez" announced that it expects to receive funding from Central Bank of the Russian Federation CI
27/04/22 Public Joint-Stock Company "Pharmsynthez" Auditor Raises 'Going Concern' Doubt CI
11/11/21 Public Joint-Stock Company "Pharmsynthez" Reports Earnings Results for the Half Year Ended June 30, 2021 CI
15/10/21 Xenetic Biosciences, Inc. Enters into Amendment Number One to Master Services Agreement with PJSC Pharmsynthez CI
5 years 2.64
Extreme 2.645
6.88
10 years 2.64
Extreme 2.645
18.1
Manager TitleAgeSince
Chief Executive Officer 48 31/12/2013
Director of Finance/CFO 47 -
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 57 31/12/2004
Director/Board Member 58 -
Director/Board Member 47 -
Change 5-day change 1-year change 3-year change Capi.($)
+10.15%-.--%-.--%-.--% 25.27M
-0.82%+1.40%+39.64%+143.17% 1,275B
-1.12%+0.16%+44.21%+88.24% 680B
-0.16%+0.43%+26.76%+113.01% 521B
+1.14%+2.04%+43.06%+72.81% 389B
-2.23%-2.89%+55.47%+41.64% 356B
+1.27%+1.72%+30.01%+63.11% 305B
+0.37%-0.23%+3.71%+38.05% 287B
-0.72%-0.63%+37.29%+71.87% 250B
-0.30%-1.03%+34.04%+124.88% 208B
Average +0.76%+1.47%+31.42%+75.68% 427B
Weighted average by Cap. -0.47%+0.76%+36.92%+98.02%

Financials

2024 2025
Net sales 247M 3M 2.72M 2.51M 2.27M 4.29M 281M 4.44M 30.24M 11.98M 151M 11.24M 11M 478M 156M 1.89M 1.72M 1.59M 1.43M 2.7M 177M 2.8M 19.06M 7.55M 95.16M 7.09M 6.94M 301M
Net income 254M 3.08M 2.8M 2.59M 2.34M 4.41M 289M 4.56M 31.1M 12.32M 155M 11.56M 11.32M 492M -254M -3.08M -2.79M -2.58M -2.33M -4.4M -289M -4.56M -31.04M -12.3M -155M -11.54M -11.3M -491M
Net Debt 360M 4.36M 3.96M 3.66M 3.31M 6.24M 409M 6.46M 44.02M 17.44M 220M 16.36M 16.02M 696M 360M 4.36M 3.96M 3.66M 3.3M 6.23M 409M 6.45M 43.97M 17.42M 219M 16.35M 16M 695M
Projected Income Statement - Annual - Pharmsynthez
Logo Pharmsynthez
Farmsintez PAO (Farmsintez OJSC) is a Russia-based company, which is engaged in the pharmaceutical sector. The Company focuses on the medical research, development and manufacture of drugs ingredients used in oncology, gynecology, tuberculosis therapy and others. In addition, Farmsintez OAO offers chemical research services, chemical technology development and quality control services. The Company sells its products domestically, as well as abroad, including the Commonwealth of Independence State (CIS) countries. It has two wholly owned subsidiaries located in Moscow and Tallin, Estonia. As of May 21, 2011, the Company’s major shareholder was EphaG AS with a stake of 69.23%. In April 2013, the Company acquired the pharmacies of Guardum Pharmaceuticals in the U.S. state of Florida.
Employees
59
  1. Stock Market
  2. Stocks
  3. LIFE Stock